Table 2 Human papillomavirus (HPV) by age and human immunodeficiency (HIV) status in women
| Â | All women | HIV-positive women | HIV-negative women | P-valuea |
|---|---|---|---|---|
N = 484 | N = 277 | N = 207 |  | |
Any HPV | ||||
 All women | 58.1 % (281/484) | 74.0 % (205/277) | 36.7 % (76/207) | <0.0001 |
  18–25 years | 74.1 % (63/85) | 86.4 % (38/44) | 61.0 % (25/41) | 0.008 |
  26–35 years | 59.0 % (111/188) | 68.2 % (88/129) | 39.0 % (23/59) | 0.0002 |
  36–45 years | 50.0 % (67/134) | 73.2 % (52/71) | 23.8 % (15/63) | <0.0001 |
  46–66 years | 51.9 % (40/77) | 81.8 % (27/33) | 29.5 % (13/44) | <0.0001 |
Multiple HPV infections | ||||
 All women | 34.3 % (166/484) | 49.8 % (138/277) | 13.5 % (28/207) | <0.0001 |
  18–25 years | 47.1 % (40/85) | 61.4 % (27/44) | 31.7 % (13/41) | 0.007 |
  26–35 years | 34.6 % (65/188) | 45.0 % (58/129) | 11.9 % (7/59) | <0.0001 |
  36–45 years | 30.6 % (41/134) | 49.3 % (35/71) | 9.5 % (6/63) | <0.0001 |
  46–66 years | 26.0 % (20/77) | 54.5 % (18/33) | 4.5 % (2/44) | <0.0001 |
Single HPV infection | ||||
 All women | 23.8 % (115/484) | 24.2 % (67/277) | 23.2 % (48/207) | 0.800 |
  18–25 years | 27.1 % (23/85) | 25.0 % (11/44) | 29.3 % (12/41) | 0.664 |
  26–35 years | 24.5 % (46/188) | 23.3 % (30/129) | 27.1 % (16/59) | 0.570 |
  36–45 years | 19.4 % (26/134) | 23.9 % (17/71) | 14.3 % (9/63) | 0.161 |
  46–66 years | 26.0 % (20/77) | 27.3 % (9/33) | 25.0 % (11/44) | 0.828 |
HR-HPV | ||||
 All women | 39.5 % (191/484) | 52.0 % (144/277) | 22.7 % (47/207) | <0.0001 |
  18–25 years | 54.1 % (46/85) | 72.7 % (32/44) | 34.1 % (14/41) | 0.0004 |
  26–35 years | 37.2 % (70/188) | 40.3 % (52/129) | 30.5 % (18/59) | 0.199 |
  36–45 years | 41.8 % (56/134) | 64.8 % (46/71) | 15.9 % (10/63) | <0.0001 |
  46–66 years | 24.7 % (19/77) | 42.4 % (14/33) | 11.4 % (5/44) | 0.002 |
Probable HR-HPV | ||||
 All women | 21.1 % (102/484) | 30.7 % (85/277) | 8.2 % (17/207) | <0.0001 |
  18–25 years | 25.9 % (22/85) | 34.1 % (15/44) | 17.1 % (7/41) | 0.080 |
  26–35 years | 27.1 % (51/188) | 37.2 % (48/129) | 5.1 % (3/59) | <0.0001 |
  36–45 years | 15.7 % (21/134) | 22.5 % (16/71) | 7.9 % (5/63) | 0.02 |
  46–66 years | 10.4 % (8/77) | 18.2 % (6/33) | 4.5 % (2/44) | 0.055 |
LR-HPV | ||||
 All women | 34.5 % (167/484) | 49.8 % (138/277) | 14.0 % (29/207) | <0.0001 |
  18–25 years | 44.7 % (38/85) | 63.6 % (28/44) | 24.4 % (10/41) | 0.0003 |
  26–35 years | 36.7 % (69/188) | 48.1 % (62/129) | 11.9 % (7/59) | <0.0001 |
  36–45 years | 26.9 % (36/134) | 43.7 % (31/71) | 7.9 % (5/63) | <0.0001 |
  46–66 years | 31.2 % (24/77) | 51.5 % (17/33) | 15.9 % (7/44) | 0.0006 |